Forest Laboratories news from FierceHealthcare
NewsInsomnia costing $42B a year; Minorities, poor less likely to see doctors with EMRs;
> A new report from Sanofi-Aventis and The Center for Medicine in the Public Interest contends that delays in insomnia diagnosis and treatment is costing the U.S. at least $42 billion in direct Read more...
Federal prosecutors: Psychiatrist paid to tout off-label antidepressant use
Federal prosecutors have unveiled a case against pharmaceutical company Forest Laboratories, charging that the company illegally marketed antidepressants Celexa and Lexapro for use in children. In a Read more...
| Press ReleasesPatent Expiries Will Contribute to Growth Rate Decline in Respiratory Therapeutics Market: companiesandmarkets.comRespiratory therapeutics market valued at $30.1 billion in 2010Average cost of respiratory disorder treatment valued at $611 p/aRespiratory disorders include: allergic rhinitis, asthma, COPD and Read more >> Forest Laboratories Chairman and CEO to Challenge “Unwarranted and Unprecedented” Potential Action to Exclude Him from FedPotential HHS-OIG Action Does Not Allege Any WrongdoingBy Howard Solomon, Company’s Chairman, CEO & President If Necessary, Solomon Will Defend Position In Court Vigorously Solomon to Continue in Read more >> Forest Laboratories Enters Collaboration on Bystolic® and Savella® in CanadaNEW YORK--(BUSINESS WIRE)-- Forest Laboratories, Inc. (Forest) (NYSE: FRX) today announced that Forest Laboratories Holdings Limited, its wholly owned subsidiary, has entered into a definitive Read more >> |
